Simone Fulda

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Fulda Simone
Exploiting apoptosis pathways for the treatment of pediatric cancers.
Fulda S
The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
Westhoff Mike-Andrew; Fulda Simone
Adhesion-mediated apoptosis resistance in cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Simone Fulda (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Fulda Simone
Exploiting apoptosis pathways for the treatment of pediatric cancers.
Pediatric blood & cancer 2009;53(4):533-6.
2009: Fulda S
The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
Current cancer drug targets 2009;9(6):729-37.
2009: Westhoff Mike-Andrew; Fulda Simone
Adhesion-mediated apoptosis resistance in cancer.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2009;12(4-5):127-36.
2009: Vellanki Sri Hari Krishna; Grabrucker Andreas; Liebau Stefan; Proepper Christian; Eramo Adriana; Braun Veit; Boeckers Tobias; Debatin Klaus-Michael; Fulda Simone
Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma.
Neoplasia (New York, N.Y.) 2009;11(8):743-52.
2009: Fulda Simone
Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia.
British journal of haematology 2009;145(4):441-54.
2009: Fulda Simone
Cell death in hematological tumors.
Apoptosis : an international journal on programmed cell death 2009;14(4):409-23.
2009: Vogler Meike; Walczak Henning; Stadel Dominic; Haas Tobias L; Genze Felicitas; Jovanovic Marjana; Bhanot Umesh; Hasel Cornelia; Möller Peter; Gschwend Jürgen E; Simmet Thomas; Debatin Klaus-Michael; Fulda Simone
Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Cancer research 2009;69(6):2425-34.
2009: Ammann Johannes U; Haag Christian; Kasperczyk Hubert; Debatin Klaus-Michael; Fulda Simone
Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition.
International journal of cancer. Journal international du cancer 2009;124(6):1301-11.
2009: Fulda Simone
Tumor resistance to apoptosis.
International journal of cancer. Journal international du cancer 2009;124(3):511-5.
2009: Fulda Simone
Betulinic acid: a natural product with anticancer activity.
Molecular nutrition & food research 2009;53(1):140-6.
2009: Fulda S
Apoptosis pathways and neuroblastoma therapy.
Current pharmaceutical design 2009;15(4):430-5.
2008: Vogler Meike; Walczak Henning; Stadel Dominic; Haas Tobias L; Genze Felicitas; Jovanovic Marjana; Gschwend Jürgen E; Simmet Thomas; Debatin Klaus-Michael; Fulda Simone
Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Cancer research 2008;68(19):7956-65.
2008: Opel Daniela; Westhoff Mike-Andrew; Bender Ariane; Braun Veit; Debatin Klaus-Michael; Fulda Simone
Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
Cancer research 2008;68(15):6271-80.
2008: Gatz Susanne Andrea; Keimling Marlen; Baumann Cindy; Dörk Thilo; Debatin Klaus-Michael; Fulda Simone; Wiesmüller Lisa
Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner.
Carcinogenesis 2008;29(3):519-27.
2008: Strauss G; Westhoff M-A; Fischer-Posovszky P; Fulda S; Schanbacher M; Eckhoff S M; Stahnke K; Vahsen N; Kroemer G; Debatin K-M
4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG.
Cell death and differentiation 2008;15(2):332-43.
2008: Ehrhardt H; Häcker S; Wittmann S; Maurer M; Borkhardt A; Toloczko A; Debatin K-M; Fulda S; Jeremias I
Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.
Oncogene 2008;27(6):783-93.
2007: Azoitei N; Brey A; Busch T; Fulda S; Adler G; Seufferlein T
Thirty-eight-negative kinase 1 (TNK1) facilitates TNFalpha-induced apoptosis by blocking NF-kappaB activation.
Oncogene 2007;26(45):6536-45.
2007: Giagkousiklidis S; Vellanki S H; Debatin K-M; Fulda S
Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition.
Oncogene 2007;26(49):7006-16.
2007: Ji Ping; Bäumer Nicole; Yin Taijun; Diederichs Sven; Zhang Feng; Beger Carmela; Welte Karl; Fulda Simone; Berdel Wolfgang E; Serve Hubert; Müller-Tidow Carsten
DNA damage response involves modulation of Ku70 and Rb functions by cyclin A1 in leukemia cells.
International journal of cancer. Journal international du cancer 2007;121(4):706-13.
2007: Fulda Simone; Debatin Klaus-Michael
HIF-1-regulated glucose metabolism: a key to apoptosis resistance?
Cell cycle (Georgetown, Tex.) 2007;6(7):790-2.
2007: Opel Daniela; Poremba Christopher; Simon Thorsten; Debatin Klaus-Michael; Fulda Simone
Activation of Akt predicts poor outcome in neuroblastoma.
Cancer research 2007;67(2):735-45.
2007: La Ferla-Brühl K; Westhoff M A; Karl S; Kasperczyk H; Zwacka R M; Debatin K M; Fulda S
NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition.
Oncogene 2007;26(4):571-82.
2007: Vogler M; Dürr K; Jovanovic M; Debatin K-M; Fulda S
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells.
Oncogene 2007;26(2):248-57.
2006: Corbacioglu Selim; Kilic Mehtap; Westhoff Mike-Andrew; Reinhardt Dirk; Fulda Simone; Debatin Klaus-Michael
Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin.
Blood 2006;108(10):3504-13.
2006: Fulda Simone; Poremba Christopher; Berwanger Bernd; Häcker Sabine; Eilers Martin; Christiansen Holger; Hero Barbara; Debatin Klaus-Michael
Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma.
Cancer research 2006;66(20):10016-23.
2006: Fulda S; Debatin K-M
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy.
Oncogene 2006;25(34):4798-811.
2005: Giagkousiklidis Stavros; Vogler Meike; Westhoff Mike-Andrew; Kasperczyk Hubert; Debatin Klaus-Michael; Fulda Simone
Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase.
Cancer research 2005;65(22):10502-13.
2005: Vogler Meike; Giagkousiklidis Stavros; Genze Felicitas; Gschwend Juergen E; Debatin Klaus-Michael; Fulda Simone
Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity.
Oncogene 2005;24(48):7190-202.
2005: Fulda Simone; Debatin Klaus-Michael
HDAC inhibitors: double edge sword for TRAIL cancer therapy?
Cancer biology & therapy 2005;4(10):1113-5.
2005: Kasperczyk Hubert; La Ferla-Brühl Katia; Westhoff Mike Andrew; Behrend Lars; Zwacka Ralf Michael; Debatin Klaus-Michael; Fulda Simone
Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy.
Oncogene 2005;24(46):6945-56.
2005: Fulda Simone; Debatin Klaus-Michael
Sensitization for anticancer drug-induced apoptosis by betulinic Acid.
Neoplasia (New York, N.Y.) 2005;7(2):162-70.
2004: Fulda Simone; Debatin Klaus-Michael
Apoptosis signaling in tumor therapy.
Annals of the New York Academy of Sciences 2004;1028():150-6.
2004: Fulda Simone; Debatin Klaus-Michael
Exploiting death receptor signaling pathways for tumor therapy.
Biochimica et biophysica acta 2004;1705(1):27-41.
2004: Fulda Simone; Debatin Klaus-Michael
Targeting apoptosis pathways in cancer therapy.
Current cancer drug targets 2004;4(7):569-76.
2004: Fulda Simone; Jeremias Irmela; Debatin Klaus-Michael
Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells.
Oncogene 2004;23(46):7611-20.
2004: Fulda Simone; Debatin Klaus-Michael
Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol.
Oncogene 2004;23(40):6702-11.
2004: Ehrhardt H; Fulda S; Führer M; Debatin K M; Jeremias I
Betulinic acid-induced apoptosis in leukemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(8):1406-12.
2004: Fulda Simone; Debatin Klaus-Michael
Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol.
Cancer research 2004;64(1):337-46.
2003: Van Valen Frans; Fulda Simone; Schäfer Karl-Ludwig; Truckenbrod Borna; Hotfilder Marc; Poremba Christopher; Debatin Klaus-Michael; Winkelmann Winfried
Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells.
International journal of cancer. Journal international du cancer 2003;107(6):929-40.
2003: Fulda Simone; Debatin Klaus Michael
Apoptosis pathways in neuroblastoma therapy.
Cancer letters 2003;197(1-2):131-5.
2003: Fulda Simone; Debatin Klaus-Michael
Death receptor signaling in cancer therapy.
Current medicinal chemistry. Anti-cancer agents 2003;3(4):253-62.
2003: Ehrhardt Harald; Fulda Simone; Schmid Irene; Hiscott John; Debatin Klaus-Michael; Jeremias Irmela
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.
Oncogene 2003;22(25):3842-52.
2003: Debatin Klaus Michael; Stahnke Karsten; Fulda Simone
Apoptosis in hematological disorders.
Seminars in cancer biology 2003;13(2):149-58.
2002: Liptay Susanne; Fulda Simone; Schanbacher Marta; Bourteele Soizic; Ferri Karine F; Kroemer Guido; Adler Guido; Debatin Klaus M; Schmid Roland M
Molecular mechanisms of sulfasalazine-induced T-cell apoptosis.
British journal of pharmacology 2002;137(5):608-20.
2002: Fulda Simone; Wick Wolfgang; Weller Michael; Debatin Klaus-Michael
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Nature medicine 2002;8(8):808-15.
2002: Beltinger Christian; Fulda Simone; Walczak Henning; Debatin Klaus-Michael
TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells.
Cancer gene therapy 2002;9(4):372-81.
2002: Fulda Simone; Debatin Klaus-Michael
IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway.
Oncogene 2002;21(15):2295-308.
2002: Fulda Simone; Meyer Eric; Debatin Klaus-Michael
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.
Oncogene 2002;21(15):2283-94.
2001: Stahnke K; Fulda S; Friesen C; Strauss G; Debatin K M
Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy.
Blood 2001;98(10):3066-73.
2001: Fulda S; Küfer M U; Meyer E; van Valen F; Dockhorn-Dworniczak B; Debatin K M
Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.
Oncogene 2001;20(41):5865-77.
2001: Fulda S; Meyer E; Friesen C; Susin S A; Kroemer G; Debatin K M
Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis.
Oncogene 2001;20(9):1063-75.
2000: Fulda S; Debatin K M
Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors.
Medical and pediatric oncology 2000;35(6):616-8.
2000: Fulda S; Lutz W; Schwab M; Debatin K M
MycN sensitizes neuroblastoma cells for drug-triggered apoptosis.
Medical and pediatric oncology 2000;35(6):582-4.
2000: Van Valen F; Fulda S; Truckenbrod B; Eckervogt V; Sonnemann J; Hillmann A; Rödl R; Hoffmann C; Winkelmann W; Schäfer L; Dockhorn-Dworniczak B; Wessel T; Boos J; Debatin K M; Jürgens H
Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).
International journal of cancer. Journal international du cancer 2000;88(2):252-9.
2000: Fulda S; Meyer E; Debatin K M
Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Cancer research 2000;60(14):3947-56.
2000: Beltinger C; Fulda S; Kammertoens T; Uckert W; Debatin K M
Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis.
Cancer research 2000;60(12):3212-7.
2000: Fulda S; Strauss G; Meyer E; Debatin K M
Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells.
Blood 2000;95(1):301-8.
1999: Friesen C; Fulda S; Debatin K M
Cytotoxic drugs and the CD95 pathway.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(11):1854-8.
1999: Fulda S; Jeremias I; Pietsch T; Debatin K M
Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors.
Klinische Pädiatrie 1999;211(4):319-22.
1999: Beltinger C; Fulda S; Kammertoens T; Meyer E; Uckert W; Debatin K M
Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(15):8699-704.
1999: Fulda S; Jeremias I; Steiner H H; Pietsch T; Debatin K M
Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells.
International journal of cancer. Journal international du cancer 1999;82(3):435-41.
1999: Friesen C; Fulda S; Debatin K M
Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells.
Cell death and differentiation 1999;6(5):471-80.
1999: Fulda S; Lutz W; Schwab M; Debatin K M
MycN sensitizes neuroblastoma cells for drug-induced apoptosis.
Oncogene 1999;18(7):1479-86.
1998: Fulda S; Scaffidi C; Susin S A; Krammer P H; Kroemer G; Peter M E; Debatin K M
Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid.
The Journal of biological chemistry 1998;273(51):33942-8.
1998: Fulda S; Scaffidi C; Pietsch T; Krammer P H; Peter M E; Debatin K M
Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells.
Cell death and differentiation 1998;5(10):884-93.
1998: Fulda S; Susin S A; Kroemer G; Debatin K M
Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells.
Cancer research 1998;58(19):4453-60.
1998: Fulda S; Friesen C; Debatin K M
Molecular determinants of apoptosis induced by cytotoxic drugs.
Klinische Pädiatrie 1998;210(4):148-52.
1998: Lutz W; Fulda S; Jeremias I; Debatin K M; Schwab M
MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells.
Oncogene 1998;17(3):339-46.
1998: Fulda S; Los M; Friesen C; Debatin K M
Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system.
International journal of cancer. Journal international du cancer 1998;76(1):105-14.
1998: Scaffidi C; Fulda S; Srinivasan A; Friesen C; Li F; Tomaselli K J; Debatin K M; Krammer P H; Peter M E
Two CD95 (APO-1/Fas) signaling pathways.
The EMBO journal 1998;17(6):1675-87.
1997: Friesen C; Fulda S; Debatin K M
Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(11):1833-41.
1997: Fulda S; Friesen C; Los M; Scaffidi C; Mier W; Benedict M; Nuñez G; Krammer P H; Peter M E; Debatin K M
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors.
Cancer research 1997;57(21):4956-64.
1997: Los M; Herr I; Friesen C; Fulda S; Schulze-Osthoff K; Debatin K M
Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases).
Blood 1997;90(8):3118-29.
1997: Fulda S; Sieverts H; Friesen C; Herr I; Debatin K M
The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells.
Cancer research 1997;57(17):3823-9.
1997: Debatin K M; Beltinger C; Böhler T; Fellenberg J; Friesen C; Fulda S; Herr I; Los M; Scheuerpflug C; Sieverts H; Stahnke K
Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction.
Biochemical Society transactions 1997;25(2):405-10.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Simone Fulda

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Simone Fulda (preview)

All Publications